There are two important updates this week that are worth paying attention to.
They may not feel urgent today—but they will shape:
- Client conversations
- Your strategy
- And how you think about your business going into AEP
Let's break them down simply.
1. The GLP‑1 "Bridge Program" Is Here
Starting July 1, 2026, CMS is launching a new program that gives Medicare beneficiaries access to GLP‑1 weight loss medications.
Here's what to know:
- Eligible clients can get these drugs for about $50/month, a major drop from typical pricing
- It's a temporary program running through the end of 2027
- It operates outside of standard Part D coverage, using a separate system for approvals and payments
This is a big shift.
Historically, Medicare has not covered these drugs for weight loss. Now, millions of beneficiaries may qualify under specific criteria like BMI and related health conditions.
Why this matters for you:
- GLP‑1 drugs are one of the fastest growing topics in healthcare
- Clients are already hearing about them
- And many will start asking questions
Even if it's not directly tied to plan selection right now…
It's becoming part of the conversation
2. 2027 Medicare Advantage Commissions Are Increasing
CMS also released the 2027 commission rates, and there's a steady increase.
Here's the big picture:
- Medicare Advantage commissions are up about 4–5% year over year
- Part D commissions saw a larger jump—around 14%
Example (most states):
- Initial MA: $694 → $725 (+4.5%)
- Renewal MA: $347 → $363 (+~4.6%)
What this means:
- The model isn't changing—but it's reinforcing something important
- Renewals and retention are where real value comes from
- And Part D is becoming more meaningful in your overall strategy
Also important:
These are maximums—carriers don't have to pay the full amount
What This All Signals
If you zoom out, both of these updates point in the same direction:
- Healthcare is getting more complex
- Clients are being introduced to new benefits and options
- And the industry keeps evolving underneath you
For agents, that means:
It's not just about selling anymore
It's about guiding, educating, and retaining
Simple Takeaway This Week
Stay aware of what's changing—but don't overcomplicate it.
- Be ready for new conversations around GLP‑1 drugs
- Understand how commissions evolve (but don't rely on them alone)
- Keep focusing on building long-term client relationships
That's where stability—and real value—comes from.
P.S. If there's something you're seeing in the field or hearing from clients, we'd love to know. We can break it down in future Book X Weekly updates.